A fruitful Discovery of proton pump inhibitors and its future

Ahmad Mehboob,V. Vikash,L. Hesheng
Abstract:Acid related diseases like erosive eosophagitis, GERD and H.Pylori resistance are major future health-care concerns. In the past 50 years despite the dramatic success of pharmacological acid suppression, challenges remains in treatment and management of ARDs. The discovery of histamine receptors, H2RBs, antacids, many other antisecretory drugs and later the PPIs played a memorable role in treating ARDs. PPIs still play and will continue to play a major role in treating hypersecretory states. But some ARDs needs complete inhibition of acid secretion as known to all, PPIs cannot completely inhibit acid secretion. Several new drugs are currently being investigated to provide significant advance over current treatments. PCABs (novoprazan) which are already approved in some countries are among new drugs that promise complete inhibition of acid secretion, safe and well tolerated compared to PPIs. Clinicians will continue to rely on PPIs as first line therapy for ARDs. Taking all the above considerations into account there is room for improvement in treating ARDs, to obtain ideal PCABs to overcome the limitations of PPIs. In this review we compared the efficacy of a PCAB (Vonoprazan) to (Lansoprazole) a well-known PPI. The results proved that Vonoprazan a potassium competitive acid blocker is non-inferior to Lansoprazole in efficacy but safe and well tolerated drug in treating 1 Corresponding author e-mail: xhnk@163.com.renmin Ahmad Muhammad Mehboob, V Vikash, Luo HeshengA fruitful Discovery of proton pump inhibitors and its future EUROPEAN ACADEMIC RESEARCH Vol. IV, Issue 12 / March 2017 10635 GERD, healing erosive eosophagitis and eradicating H.Pylori infection.
What problem does this paper attempt to address?